Bayer's Monsanto unit appeared before a Missouri judge on September 14 to seek final approval of a $7.25 billion class-action settlement aimed at resolving nearly all current and future U.S. lawsuits alleging that its Roundup weedkiller causes cancer. The company argued there is no alternative path forward, with its attorney stating plainly: "This is the settlement. There is not another settlement."

The proposed deal would pay out between $10,000 and $165,000 to individuals who developed non-Hodgkin lymphoma after exposure to Roundup, with award amounts varying based on cancer severity, age at diagnosis, and exposure setting. Supporters — including attorneys representing thousands of plaintiffs — point to a landmark June 2026 Supreme Court ruling (7-2) that blocked state-level "failure-to-warn" claims against Bayer, significantly weakening the legal standing of many individual lawsuits. Opponents argue the payouts are inadequate, particularly given that Roundup remains on the market and some studies suggest 80% of Americans have been exposed to glyphosate.

By the Numbers:

• $7.25B — total proposed settlement value
• ~65,000 — active Roundup cancer claims in U.S. courts
• $10,000–$165,000 — individual payout range for non-Hodgkin lymphoma claimants
• $675M — attorneys' fees sought by negotiating lawyers
• ~$10B — amount Bayer previously paid in 2020 to resolve earlier Roundup claims

Why it matters: The outcome of this settlement could set a significant precedent for how mass tort litigation involving widely used consumer products is resolved — especially when federal regulatory approval conflicts with state-level public health concerns. For the oncology and public health communities, the case also keeps the spotlight on glyphosate's contested cancer risk, with the EPA's updated human health risk assessment still pending.